New research reports that targeting the asialoglycoprotein receptor (ASGR1) in mice promotes cholesterol excretion through a mechanism involving stabilization of LXR without lipogenesis activation, strengthening the idea of therapeutically targeting ASGR1 to lower blood cholesterol and risk of atherosclerotic cardiovascular disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Rader, D. J. Cell Metab. 23, 405–412 (2016).
Nurmohamed, N. S., Navar, A. M. & Kastelein, J. J. P. Am. Coll. Cardiol. 77, 1564–1575 (2021).
Nioi, P. et al. N. Engl. J. Med. 374, 2131–2141 (2016).
Wang, J. Q. et al. Nature https://doi.org/10.1038/s41586-022-05006-3 (2022).
Igdoura, S. A. Curr. Opin. Lipidol. 28, 209–212 (2017).
Rensen, P. C. N. et al. J. Med. Chem. 47, 5798–5808 (2004).
Springer, A. D. & Dowdy, S. F. Nucleic Acid Ther. 28, 109–118 (2018).
Samuel, E. et al. Ann. Pharmacother. https://doi.org/10.1177/10600280221105169 (2022).
Barton, A. R. et al. Nat. Genet. 53, 1260–1269 (2021).
van den Boogert, M. A. W. et al. Curr. Opin. Lipidol. 28, 502–506 (2017).
Rosenson, R. S. et al. Circulation 125, 1905–1919 (2012).
Zhang, Y. et al. J. Clin. Invest. 122, 1688–1699 (2012).
Russo-Savage, L. & Schulman, I. G. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166121 (2021).
William Hancock-Cerutti, W. & Rader, D. J. J. Am. Coll. Cardiol. 63, 2129–2130 (2014).
Cohen, J. C. & Hobbs, H. H. Science 340, 689–690 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.J.R. serves on the scientific advisory boards of Alnylam, Novartis, Pfizer and Verve.
Rights and permissions
About this article
Cite this article
Rader, D.J. Targeting ASGR1 to lower cholesterol. Nat Metab 4, 967–969 (2022). https://doi.org/10.1038/s42255-022-00623-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s42255-022-00623-8